Lipocine reports Q3 2026 results, highlights BLOOM study launch for LPCN 1154Nov 5Quarterly updateLipocine Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Amneal secures three mometasone furoate labeling supplement approvals in one weekOct 30Weekly roundup, 3 itemsAmneal Pharmaceuticals, LLCmometasoneUpdated
Pfizer registers real-world observational study of marstacimab in hemophilia A and B patientsOct 9Weekly roundup, 8 itemsabrocitinibcyclophosphamide
Health Canada approves Lipocine's TLANDO for testosterone replacement therapyOct 7Regulatory decisionLipocine Inc.testosterone